Abcellera Biologics/$ABCL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abcellera Biologics
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Ticker
$ABCL
Sector
Primary listing
Employees
562
Headquarters
Vancouver, Canada
Website
ABCL Metrics
BasicAdvanced
$1.3bn
-
-$0.49
0.87
-
Price and volume
Market cap
$1.3bn
Beta
0.87
52-week high
$6.52
52-week low
$1.94
Average daily volume
4.4m
Financial strength
Current ratio
11.324
Quick ratio
10.074
Long term debt to equity
14.211
Total debt to equity
14.812
Profitability
EBITDA (TTM)
-194.932
Gross margin (TTM)
-148.68%
Net profit margin (TTM)
-194.88%
Operating margin (TTM)
-288.98%
Effective tax rate (TTM)
17.56%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-9.99%
Return on equity (TTM)
-14.47%
Valuation
Price to revenue (TTM)
16.5
Price to book
1.29
Price to tangible book (TTM)
1.42
Price to free cash flow (TTM)
-7.122
Free cash flow yield (TTM)
-14.04%
Free cash flow per share (TTM)
-0.583
Growth
Revenue change (TTM)
160.56%
Earnings per share change (TTM)
-11.42%
3-year revenue growth (CAGR)
-46.31%
3-year earnings per share growth (CAGR)
-0.66%
What the Analysts think about ABCL
Analyst ratings (Buy, Hold, Sell) for Abcellera Biologics stock.
ABCL Financial Performance
Revenues and expenses
ABCL Earnings Performance
Company profitability
ABCL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abcellera Biologics stock?
Abcellera Biologics (ABCL) has a market cap of $1.3B as of May 02, 2026.
What is the P/E ratio for Abcellera Biologics stock?
The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of May 02, 2026.
Does Abcellera Biologics stock pay dividends?
No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of May 02, 2026.
When is the next Abcellera Biologics dividend payment date?
Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Abcellera Biologics?
Abcellera Biologics (ABCL) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.